<DOC>
	<DOCNO>NCT01423812</DOCNO>
	<brief_summary>Darunavir nonpeptidic protease inhibitor high genetic barrier resistance evolve prototype compound synthesize use structure-based design strategy . Once-daily darunavir 800mg boost 100mg ritonavir effective antiretroviral agent indicate HIV-infected treatment-naïve patient . In treatment-experienced patient , darunavir initially approve twice-daily administration boost twice-daily ritonavir 600mg 100mg , respectively . Recently , once-daily darunavir/ritonavir approve use treatment-experienced adult patient viremia darunavir resistance mutation . In treatment-experienced patient viral suppression , switch antiretroviral take twice-daily once-daily dose attractive option promote great patient acceptability adherence , potentially minimize side effect toxicity . Because darunavir/ritonavir 's high genetic barrier resistance well-established safety profile once-daily dose , switch patient virologic suppression twice-daily darunavir/ritonavir once-daily darunavir/ritonavir likely confer attribute favorable patient simplify dose schedule lower potential lipid elevation without loss virologic control . DRIVESHAFT 48-week Phase 4 , randomize , open label , comparative study . The study conduct 60 HIV-1 infect , antiretroviral experience , virologically-suppressed patient regimens contain darunavir 600mg/ ritonavir 100mg twice-daily minimum two antiretrovirals , history 0-1 darunavir-associated resistance mutation . Subjects randomize 1:1 switch darunavir 800mg/ ritonavir 100mg once-daily continue current regimen . Rates virologic suppression once-daily darunavir/ritonavir regimen relative darunavir/ritonavir twice-daily regimen compare , safety , change baseline fasting lipid parameter , adherence evaluate .</brief_summary>
	<brief_title>DRIVESHAFT : Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>1 . ARTexperienced , HIV1 infect subject ≥18 year age . 2 . A female subject eligible enter participate study : 1. nonchildbearing potential define either postmenopausal ( 12 month spontaneous amenorrhea ≥45 year age ) physically incapable become pregnant document tubal ligation , hysterectomy , bilateral oophorectomy , 2. childbearing potential , negative pregnancy test Screen Day 1 agree one follow method contraception avoid pregnancy : Complete abstinence intercourse 2 week prior administration study medication , throughout study , least 2 week discontinuation study medication . Double barrier method ( male condom/spermicide , male condom/diaphragm , diaphragm/spermicide ) . Approved hormonal contraception may administer darunavir/ritonavir Any intrauterine device ( IUD ) publish data show expected failure rate &lt; 1 % per year Any method publish data show expected failure rate &lt; 1 % per year . Any contraception method must use consistently accordance approved product label . All subject participate study counsel safe sexual practice include use effective barrier method ( e.g . male condom/spermicide ) . 3 . CD4 &gt; 50 cells/mm3 4 . HIV1 RNA concentration undetectable level ( accord local assay use ) least 12 week stable current regimen 5 . Current regimen include darunavir/ritonavir 600/100 mg twicedaily plus minimum two antiretrovirals 6 . Negative serum pregnancy test screen visit Subjects meet follow criterion must enrol study : 1 . Known hypersensitivity reaction agent utilized study 2 . &gt; 1 cumulative darunavir associate mutation ( V11I , V32I , L33F , I47V , I50V , I54L M , T74P , L76V , I84V , L89V ) detect previous genotype VircoTYPE HIV1 darunavir foldchange &gt; 10.0 previous virtual phenotype 3 . Pregnant breast feed woman 4 . Liver dysfunction ChildPugh class C disease decompensated cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>treatment-experienced</keyword>
	<keyword>protease inhibitor</keyword>
	<keyword>adherence</keyword>
	<keyword>lipid</keyword>
</DOC>